Honest Criticisms and Limitations of the RECONNECT Trial
A critical examination of the RECONNECT trial's enrollment biases, follow-up gaps, statistical caveats, and generalizability concerns for bremelanotide (Vyleesi) in HSDD.
Trials Reconnect
8 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
8articles
3topic areas covered
May 25, 2026latest review
Trials Reconnect library
Showing 8 of 8 clinical reviews.
Inside the RECONNECT Methodology: What Most Summaries Skip
A detailed methodological breakdown of the RECONNECT trial for bremelanotide (Vyleesi) in HSDD, covering randomization, blinding, endpoint definitions, statistical approach, and interpretive pitfalls.
RECONNECT Cost, Cost-Effectiveness, and Health-Economic Implications
A deep-dive into the cost-effectiveness analyses built on RECONNECT trial data for bremelanotide (Vyleesi), covering cost-per-QALY modeling, payer-coverage reality, list vs. net price gaps, and the individual patient value calculation.
RECONNECT Extension Data and What Happened After the Trial Ended
Deep dive into the RECONNECT open-label extension for bremelanotide (Vyleesi) in HSDD: durability of effect, dropout patterns, long-term safety signals, and what 12+ months of data reveal beyond the key 24-week RCT.
RECONNECT Results in Detail: Numbers, Subgroups, and Time Course
A deep-dive into the RECONNECT trial's primary and secondary endpoint results for bremelanotide (Vyleesi) in HSDD, including effect sizes, confidence intervals, time-course data, and response distribution analysis.
RECONNECT Subgroup Analyses: Who Responded Most and Least to Bremelanotide
Deep-dive into the RECONNECT trial's pre-specified and post-hoc subgroup analyses for bremelanotide (Vyleesi) in HSDD, examining response differences by age, BMI, race, and baseline severity.
RECONNECT Trial: A Plain-English Overview of What It Established
A deep-dive overview of the RECONNECT trial, the key Phase 3 study behind FDA approval of bremelanotide (Vyleesi) for hypoactive sexual desire disorder in premenopausal women.
What RECONNECT Actually Changes in Clinical Practice
How the RECONNECT trial reshaped HSDD treatment with bremelanotide (Vyleesi), which guidelines updated, which prescribing patterns shifted, and what the data means for patients outside the trial population.